CURRICULUM VITAE 1/22/2021

NAME: Patricia C. Lee, M.D. **DATE: 22 January 2021**

PRESENT POSITION AND ADDRESS:

Center for Clinical Studies
451 N. Texas Avenue
Webster, TX 77598
Telephone (281) 333-2288
FAX (281) 335-4605

Center for Clinical Studies
1401 Binz St., Suite 200
Houston, TX 77004
Telephone (713) 528-8818
FAX (713) 528-8848

EDUCATION:

1975	St. Mary's University, San Antonio, Texas, B.A.
1977-1981	University of Texas at Houston, Texas Medical Center, Houston, Texas, M.D.
1981-1985	University of Texas Affiliated Hospitals, Texas Medical Center, Houston, Texas, Anatomical and Clinical Pathology
1985-1986	University of Alabama at Birmingham, Birmingham, Alabama, Surgical Pathology
1986-1987	University of Alabama at Birmingham, Birmingham, Alabama, Dermatopathology

LICENSURE INFORMATION: Texas, G7410, exp 02/28/2022

PROFESSIONAL AND TEACHING EXPERIENCE:

1992-1996 Assistant Professor of Microbiology & Immunology, UTMB, Galveston, TX

1996-2003 Associate Professor of Microbiology and Immunology (Clinical), UTMB, Galveston, TX

November 2003-present Director, Center for Clinical Studies, Webster & Houston, TX

Administration of The Center for Clinical Studies research facility in Webster & Houston. Responsible for the administration of the support staff; financial coordination of office and patient related expenses.

Recruit, screen and evaluate patients interested in participating in research clinical trials. Inform and educate patients and their accompanying family members or partners on their specific diseases with emphasis on treatment options, prevention and ongoing research. Refer non-qualifying patients to local medical facilities, physicians and support groups who can be of assistance (Houston Herpes Help Group, American Social Health Association, Center for AIDS,

National Psoriasis Foundation). Present available trials at local Houston/Galveston public conferences (NASA, Mayor's Women Conference in Houston). Outreach recruitment efforts to certain populations and local organizations, including local physicians and other medical personnel at health care organizations (Kelsey Seybold, Diagnostic, Memorial Sisters of Charity, Montrose and Gulf Coast Clinics, Planned Parenthood, UT Houston, Baylor College of Medicine, Bering, Thomas Street) in the Houston/Galveston area.

RESEARCH ACTIVITIES:

INVESTIGATOR/SUB-INVESTIGATOR:

1. SmithKline Beecham Pharmaceuticals: "Open, Non-Randomized, Dose-Escalation of Evaluation of the Efficacy and Safety of BRL 39123A in the Treatment of Mucocutaneous Herpes Simplex Infection in Immunocompromised Patients" 1991-1993.

2. Burroughs Wellcome Co.: "A Multicenter, Double-Blind, Controlled Trial Comparing Oral Acyclovir to Oral 256U87 for the Treatment of Herpes Zoster in Immunocompetent Patients 50 years of Age and Older, Protocol 05" 1991-1992.

3. Burroughs Wellcome Co.: "A Multicenter Double-Blind, Placebo-Controlled Trial Evaluating 256U87 for the Treatment of Herpes Zoster in Immunocompetent Patients Less than 50 Years of Age, Protocol 06" 1991-1992.

4. Burroughs Wellcome Co.: "A Study of Investigate the Efficacy and Safety of Orally Administered 256U87 in the Treatment of Recurrent Genital Herpes in Immunocompetent Patients, Protocol 04" 1991-1992.

5. Burroughs Wellcome Co.: "A Study to Investigate the Efficacy and Safety of 256U87 Versus Acyclovir in the Treatment of Recurrent Ano-Genital Herpes Infection in HIV Infected Patients, Protocol 08" 1991-1992.

6. Burroughs Wellcome Co.: "Comparative Trial of 256U87 and Acyclovir for the Suppression of Recurrent Anogenital Herpes Infections in HIV Infected Patients, Protocol 66-07" 1991-1995.

7. Burroughs Wellcome Co.: "A Comparative Trial of 256U87 and Acyclovir for the Treatment of First-Episode Genital Herpes Infection" 1992-1993.

8. Schering Corporation: "Treatment of Genital Herpes with Intralesional Interferon Alpha" 1991-1992.

9. Schering Corporation: "Treatment of Tinea Pedis with 1% Clotrimazole Cream" 1992-1993.

10. Schering Corporation: "Treatment of keloids with Intralesional Interferon Alpha" 1992-1993.

11. Hoffmann La Roche: "Treatment of Condyloma Acuminatum with Intralesional Interferon Alpha (Roferon™)" 1992-1993.

12. Matrix Pharmaceuticals, Inc.: MP#17-91-P "A Randomized, Double-Blind Controlled Study to Evaluate the Contributions of Components in the Therapeutic Implant 5-FU-3 TI 5003 when Administered to Patients with External Condylomata Acuminata" 1992-1993.

13. Oclassen Pharmaceuticals: "A Double-Blind Placebo Controlled Study in the Safety and Efficacy of 0.5% Podofilox Gel in the Treatment of External Genital Warts" 1992-1993.

14. Burroughs Wellcome Co.: "A Study to Investigate the Efficacy and Safety of Oral Valacyclovir (1000mg or 500mg, twice daily) Compared with Placebo in the Treatment of Recurrent Genital Herpes in Immunocompetent Patients, Protocol 028" 1992-1993.

15. 3M Pharmaceuticals: IMIQ-1005-06. "Vehicle-Controlled Safety and Efficacy Trial Evaluating Daily Overnight Application of 1% and 5% Imiquimod Cream for the Treatment of Genital/Cervical Warts" 1992-1993.

16. ISIS Pharmaceuticals: "A Randomized, Double-Blind, MultiInvestigator Clinical Evaluation of Comparing Two Single Dose Levels of ISIS 2105 with Vehicle Control for Therapy in Condyloma Acuminatum Patients" 1992-1993.

17. SmithKline Beecham Pharmaceuticals: "A Double-Blind, Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of Oral Famciclovir in the Suppression of Recurrent Genital Herpes Infection in Women, Protocol 024" 1992-1993.

18. Burroughs Wellcome Co.: A Placebo-Controlled evaluation of Acyclovir 348U87 Cream for the Treatment of Herpes Simplex Labialis Infection. Protocol P-120-008" 1993-1994.

19. SmithKline Beecham Pharmaceuticals: "A Prospective, Randomized, Double-Blind, Multicenter, Patient-Initiated Study to Compare the Efficacy of Topical 1% Penciclovir Cream with Placebo in Patients with Recurrent Herpes Simplex Labialis Infection " 1993-1994.

20. Burroughs Wellcome Co.: "A Comparative Trials of Valacyclovir with Acyclovir for the Suppression of Genital Herpes Infections in Immunocompetent Patients, Protocol 026" 1994-1995.

21. SmithKline Beecham Pharmaceuticals: "Double Blind, Double-Dummy, Randomized, Placebo-Controlled Study to Assess the Safety of Oral Famciclovir for the Suppression of Recurrent Genital Herpes Infection, Protocol 033" 1994-1995.

22. ISIS Pharmaceuticals: "Pilot Randomized, Multiple-Dose Study of Afovirsen Sodium for Surgical Adjunctive Therapy of external Condyloma Acuminatum" 1994-1995.

23. Bristol Myers Squibb: "Double-Blind Multinational Trial Comparing Sorivudine [BV-ARA-U] (SQ32, 756) Versus Acyclovir for the Treatment of Acute Localized Zoster and the Effect on Zoster-Associated Pain in Immunocompetent Subjects" 1994-1996.

24. Gilead Sciences: "Phase I/II Study of the Safety and Efficacy of Topical 1-(s)-(3-Hydroxy-2-phosphonyl-methoxypropyl) Cytosine Dihydrate (HPMPC) in the Treatment of Condyloma Acuminatum in Patients with HIV infection" 1994-1997.

25. Pfizer Pharmaceutical: "Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Safety and Efficacy Study of Tioconazole 20% in the Treatment of Distal Subungual Onychomycosis of the Toenail" 1994-1995.

26. Burroughs Wellcome Co.: "A Randomized Controlled Study of Acyclovir versus Netivudine for Treatment of Herpes Zoster, Protocol 011" 1994-1996.

27. Collaborative Study with University of Indiana: "Attitudes Regarding Herpes Vaccination" 1994-1995. Collaborative Study with St. Louis University School of Medicine: Comparison of Direct Fluorescent Antigen with Polymerase Chain Reaction for Diagnosis of Varicella Zoster Virus Infections" 1994-1998.

28. Collaborative Study with St. Louis University School of Medicine: Comparison of Direct Fluorescent Antigen with Polymerase Chain Reaction for Diagnosis of Varicella Zoster Virus Infections" 1994-1998.

29. Collaborative Study with University of Washington: "Studies of Asymptomatic Viral Shedding in Persons with Recurrent Genital Herpes" 1994-1998.

30. Glaxo Wellcome: "A Double Blind, Multicenter Study Comparing Valacyclovir with Famciclovir for the Treatment of Uncomplicated Herpes Zoster in Immunocompetent Patients 50 Years of Age and Older" 1994-1997.

31. Bristol Myers Squibb: "An Open, Multicenter Study to Determine the Effect of Sorivudine on Dihydropyrimidine Dehydrogenase Activity in Peripheral Blood Mononuclear Cells of Patients with Acute Herpes Zoster" 1995-1996.

32. Lidak Pharmaceuticals: "A Clinic Initiated, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Topical n-Docosanol 10% Cream (LIDAKOL™) in Patients with Early-Stage Episodes of Acute, Recurrent Herpes Labialis" 1995-1996.

33. SmithKline Beecham Pharmaceuticals: "A Double-Masked, Double-Dummy, Randomized, Acyclovir-Controlled, Parallel Group Study to Compare the Efficacy and

Safety of Famciclovir with Acyclovir in the Treatment of Patients with Ophthalmic Zoster" 1995-1997.

34. SmithKline Beecham Pharmaceuticals: "A Randomized, Double-Blind, Double-Dummy, Multicenter Acyclovir-Controlled Study to Assess the Safety and Efficacy of Oral Famciclovir for the Treatment of Herpes Zoster Infection in Immunocompromised Patients, Protocol 086" 1995-1997.

35. Astra Pharmaceuticals: "An Open Label Study to Evaluate the Effects of Chemical and Mechanical Methods of Skin Preparation Prior to Application of EMLA Cream on the Absorption of Lidocaine and Prilocaine and on the Effectiveness of EMLA Cream" 1996-1997.

36. Glaxo Wellcome, Inc.: "A Comparison of Oral Valtrex 500mg Twice Daily for Three or Five Days for Treatment of Recurrent Genital Herpes" 1996-1997.

37. 3M Pharmaceuticals: "Open-Label Trial Evaluating the Percutaneous Penetration of Imiquimod 5% Cream (Formulation U-2e) Following Overnight Application Three-Times Per Week for the Treatment of Genital/Perianal Warts" 1996-1997.

38. 3M Pharmaceuticals: "Vehicle-Controlled Study Investigating the Mechanism of Action of 5% Imiquimod Cream Applied Three Times a Week for the Treatment of Patients with Genital/Perianal Warts" 1996-1997.

39. SmithKline Beecham Biologicals: "An Open-Label Study to Evaluate Famciclovir in the Management of Acute Uncomplicated Herpes Zoster in Persons Infected with HIV" 1996-1997.

40. Bristol Myers Squibb: "A Randomized Double Blind, Placebo-Controlled Efficacy and Safety Study of Oral Lobucavir in Patients with Recurrent Herpes Labialis, Protocol 012" 1997-1998.

41. Bristol Myers Squibb: "A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Oral Lobucavir in Patients with Recurrent Genital Herpes, Protocol 011" 1997-1998.

42. Gilead Sciences: "A Double Blind, Placebo-Controlled Study of the Safety and Efficacy of Cidofovir Gel for the Treatment of Molluscum Contagiosum in Patients with HIV Infection" 1997-1998.

43. SmithKline Beecham Biologicals: "A Randomized, Double-Blind, Double-Dummy Study to Assess the Efficacy and Safety of Oral Famciclovir Compared to Oral Valacyclovir for the Suppression of Recurrent Genital Herpes, Protocol 210" 1997-1999.

44. SmithKline Beecham Biologicals: "A Double-Blind, Randomized, Parallel Group, Multi-Center Study, to Compare the Safety and Efficacy of 10 Days of Oral Famciclovir 750 mg Three Times a day with Oral Valacyclovir 1 g Twice a Day in Reducing the Frequency of Subsequent Lesional Recurrences of HSV-2 in Patients Following Treatment of First Episode Genital HSV-2, Protocol 191" 1997-1998.

45. Pentose: "A Phase I/II Dose-Ranging Study of the Safety and Efficacy of PEN203 in the Treatment of Common Warts" 1998-1999.

46. Pentose: "A Phase I/II Dose-Ranging Study of the Safety and Efficacy of PEN203 in the Treatment of Genital Warts" 1998-1999.

47. Glaxo Wellcome, Inc.: "Herpes Advice Consortium (Herpes Questionnaire)" 1998.

48. Abbott Laboratories: "The Safety and Efficacy of Three Doses of ABT-606 Compared to Acyclovir in the Treatment of Herpes Zoster in Immunocompetent Adults" 1998-1999.

49. Bristol Myers Squibb: "A Randomized, Double-Blind, Placebo-Controlled Trial, Genital Herpes Oral Suppression Trial (GHOST) of Oral Lobucavir, Protocol 043" 1998-1999.

50. Glaxo Wellcome, Inc.: "A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples" 1997-2002.

51. Glaxo Wellcome, Inc.: "An Open-Label Study of Valacyclovir HCl 1.5 grams bid for Treatment of Uncomplicated Herpes Zoster in Immunocompetent Patients 18 years of Age and Older" 1997-2001.

52. Glaxo Wellcome, Inc.: "A Double-Blind Study Comparing Two Doses of Valacyclovir HCl for the Treatment of Uncomplicated Herpes Zoster in Immunocompromised Patients 18 Years of Age and Older" 1997-present.

53. 3M Pharmaceuticals: "Safety and Efficacy Trial Evaluating 5% Imiquimod Cream Application to External Genital Warts and an Extended Treatment Area" 1998-2001.

54. 3M Pharmaceuticals: "A Phase II, Randomized, Double-Blind, Vehicle-Controlled, Dose-Escalating Study to Assess Safety and Preliminary Efficacy of Topical R-848 gel in the Treatment of Recurrent Herpes Genitalis" 1998-2000.

55. 3M Pharmaceuticals: "A Mechanism of Action Study of Aldara (Imiquimod) Cream 5% Applied Topically to Patients with Superficial Basal Cell Carcinoma" 1998-2000.

56. Schering-Plough Corporation: "A Phase II Proof of Principle Study Comparing Two Doses of Interleukin 10 (TENOVIL) Administered Subcutaneously to Placebo in Severe Psoriasis" 1999-2000.

57. Corixa Corporation: "A Multi-Center, Randomized, Controlled Phase II Study Evaluating the Effect of PVAC Treatment in Patients with Psoriasis, Protocol CCPV001-04" 1999-2001.

58. Glaxo Wellcome, Inc.: "A Multicenter, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention/Blockage of the Progression of Cold Sore Lesion Development, Protocol HS230028" 1999-2002.

59. Corixa Corporation: "A Multi-Center, Open-Label Study Evaluating the Effect of PVAC Treatment in Patients with Psoriasis who have been Previously Treated with PVAC or Control, Protocol CCPV001-05" 2000-2002.

60. Quidel Corporation: "HSV Antibody Test CS-0105-3" 2000.

61. Genentech: "A Phase III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter, Multidose Study to Evaluate the Efficacy and Safety of Subcutaneously Administered Anti-CD11a in Adults with Moderate to Severe Plaque Psoriasis Who are Candidates for Systemic Therapy" 2000-2002.

62. 3M Pharmaceuticals: A Phase III, Vehicle-Controlled Study of Topical R-848 0.01% Gel Applied 2 Times per Week for 3 Weeks for Each Recurrence of Herpes Genitalis over 12 Months to Prevent Subsequent Recurrences, Protocol 1404-RESI" 2000-2003.

63. Merck & Co., Inc.: "A Study to Evaluate the Cell-Mediated Immune Responses of Herpes Zoster Patients Compared to Healthy Subjects Over a Six-Month Period" 2000-2003.

64. Harvard University School of Medicine: "Efficacy of Riluzole in the Prevention of Postherpetic Neuralgia" 2001-2003.

65. GlaxoSmithKline: "A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate Daily Suppressive Therapy with Valtrex on the Rate of HSV Shedding in Patients with Recurrent Genital Herpes" 2001-2002.

66. 3M Pharmaceutical: "Resiquimod (R-848) 0.01% gel (U-1j) for the Treatment of Herpes Genitalis to Prevent Recurrences, Protocol 1419-RESI" 2001- 2003.

67. Quidel Corporation: "Quick-Vue Herpes Simplex Antibody Test Clinical Trial Part 2" 2002.

68. GlaxoSmithKline: "A Randomized, Double-Blind, Multicenter Study of Valtrex 500 mg Suppressive Therapy in the Reduction of Anxiety Associated with Recurrent Genital Herpes, Protocol HS240021" 2002.

69. Corixa Corporation: "A Multi-center, Randomized, Placebo-Controlled Phase 2 Study Evaluating the Effect of 15mg PVAC Treatment in Patients with Psoriasis, Protocol CCPV001-06" 2002-2003.

70. Genentech: "A Phase IIB, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults with Moderate to Severe Plaque Psoriasis, Protocol ACD2390g" 2002-2003.

71. Genentech: "An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab Followed by Efalizumab Taper in Adults with Plaque Psoriasis Previously Enrolled in Study ACD2391g" 2002-2003.

72. GlaxoSmithKline: "An Open-label Pilot Study of Valtrex 2g for One Day in the Episodic Treatment of Recurrent Genital Herpes, Protocol R-94" 2002.

73. Merck & Co., Inc.: "Protocol for Obtaining Clinical Specimens to Support Validation of a Polymerase Chain Reaction and a Direct Fluorescent Antibody Assay for Detection of Varicella-Zoster Virus, Protocol 008-00" 2002.

74. 3M Pharmaceuticals: "A Study of Local Immunologic Effects of Resiquimod 0.01% Gel Applied Topically to Herpes Lesions of Subjects with Recurrent Herpes Genitalis, Protocol 1438-RESI" 2002-2003.

75. Immunex/Amgen: "A Phase III, Multicenter Study of the Safety and Efficacy of Enbrel (etanercept) in Psoriasis, Protocol 16.0042" 2002-2003.

76. GlaxoSmithKline: "A Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Three Dose Levels of Rosiglitazone Maleate in the Treatment of Chronic Plaque Psoriasis, Protocol 330", 2003-2004. **Principal Investigator**

77. Novartis: "A 26-week, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the incidence of atopic dermatitis flares when ASM981 (pimecrolimus) cream 1% is used at the first signs and/or symptoms of atopic dermatitis and its safety and tolerability in adults 18 years of age and older, Protocol CASM981C2316", 2003-2004.

78. Novartis: "A six month open label, randomized, multi-center study to evaluate the comparative efficacy and safety of oral Famvir (Famciclovir) in the episodic (125 mg bid for 5 days) and suppressive treatment (250mg bid) of recurrent genital herpes., Protocol CFAM810AUS07", 2003-2005. **Principal Investigator**

79. Immunex/Amgen: "An Open-label, Long-term Extension Study to Assess the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects, Protocol 2003115", 2003-2005. **Principal Investigator**

80. Amgen: "A Phase 3 Multicenter Study to Assess the Efficacy and Safety of Etanercept 50 mg Twice Weekly in Psoriasis, Protocol 20030117", 2003-2007. **Principal Investigator**

81. Amgen: "A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Improvement of Joint and skin Disease in Subjects with Psoriatic Arthritis Receiving Enbrel, Protocol 20030106", 2003-2005. **Principal Investigator**

82. Novartis: "A Randomized, Multicenter, Double-Blind Controlled Study to compare the effectiveness of a single dose (1500 mg) of Famciclovir, one day (750 MgQ12) of Famciclovir and placebo in patient-initiated episodic treatment of recurrent herpes labialis, Protocol CFAM810A-2403", 2003-2005. **Principal Investigator**

83. Novartis: "Randomized, double-blind, placebo controlled multi-center study to assess the efficacy and safety of a patient initiated 1-day treatment with famciclovir 1000 mg b.i.d. for recurrent genital herpes infection for immunocompetent patients, Protocol CFAM810A-2402", 2003-2005.

84. Novartis: "A 6-week randomized, multicenter, double-blind, placebo-controlled, parallel group study to investigate the efficacy and safety of Elidel Cream 1% in patients with mild to moderate chronic hand dermatitis, followed by a 6-week open label phase to assess the safety of Elidel Cream 1%, Protocol CASM9812301", 2004-2005.

85. GlaxoSmithKline: "A Randomized, Double-Blind, Placebo-Controlled, Multicenter 60-Day Study Comparing the Efficacy of Valtrex 1 Gram Once Daily vs. Placebo Once Daily in Reducing Viral Shedding in Immunocompetent Subjects with Recurrent HSV-2 Genital Herpes, Protocol HS2100273", 2004-2005.

86. Medicis Pharmaceutical Corp.: "A Randomized, Double-Blind, Placebo-Controlled Phase III Study of an Extended-Release Formulation of Minocycline for the Treatment of the Inflammatory Lesions of Acne Vulgaris, Protocol MP-0104-05", 2004-2005. **Principal Investigator**

87. GlaxoSmithKline: "An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valaciclovir 1g Once Daily vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Infected Immunocompetent Subjects, Protocol HS2100275", 2004-2007. **Principal Investigator**

88. Fujisawa: "A Phase 3, Randomized, Double-Blind Study To Evaluate The Efficacy And Safety Of Once Daily 0.3% Tacrolimus Gel Versus Gel Vehicle In The Treatment Of Psoriasis, Protocol 03-0-169", 2004-2005. **Principal Investigator**

89. Amgen: "A Multicenter, Open-label, Prospective Study to Evaluate the Effectiveness and Safety of Etanercept in the Treatment of Subjects with Psoriasis, Protocol 20040190", 2004-2005. **Principal Investigator**

90. XenoPort, Inc.: "A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study Assessing the Safety and Efficacy of XP13512 in Patients with Postherpetic Neuralgia, Protocol XP009", 2004-2005.

91. Serono: "A Multicentre, Randomized, Double Blind, Controlled Phase III Study of Subcutaneously Administered Onercept in the Treatment and Re-Treatment of Subjects with Moderate to Severe Plaque Psoriasis", 2004-2005. **Principal Investigator**

92. Pfizer Pharmaceutical: "A Double-Blind Randomized Placebo-Controlled Trial of the Time to Onset of Meaningful Pain Relief in Subjects with Postherpetic Neuralgia (PHN) Treated with Pregabalin 150-600mg/day Flexible Optimized Dose or 300 mg/day Fixed Dose or Placebo, Protocol A0081004", 2004-2005.

93. GlaxoSmithKline: "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Way Crossover Study to Investigate the Effect of Valtrex 1g Once Daily for 60 Days on Viral Shedding in HSV-2 Seropositive Subjects with No Previous History of Symptomatic Gential Herpes Infection, Protocol VLX103596", 2005-2006.

94. Corgentech Inc.: "A Phase 1/2 Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Safety of Repeated Topical Application of Three Concentrations of NF-kappaB Decoy in Adults with Mild-to-Moderate Atopic Dermatitis, Protocol 110-01P", 2005-2006.

95. Astellas Pharma: "A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of BID Application of Tacrolimus Cream-B 0.1% Versus Cream-B Vehicle in the Treatment of Psoriasis. Protocol 04-0-206", 2005-2007.

96. LEO Pharmaceutical Products, Ltd.: "MBL 0502 US : Calcipotriene plus Betamethasone Dipropionate Gel compared to the Gel Vehicle in Scalp Psoriasis, in Patients receiving Calcipotriene plus Betamethasone Dipropionate Ointment for Psoriasis Vulgaris of Trunk/Limbs", 2005-2007.

97. Genentech, Inc.: "Protocol ACD3101g: Raptiva epidemiologic study of psoriasis outcomes and safety events (RESPONSE) in patients with chronic moderate to severe plaque psoriasis", 2005-2007. **Principal Investigator**

98. Janus Pharmaceuticals, Inc.: "A phase II, multi-center, placebo controlled, safety, efficacy and absorption evaluation of ARYS-01 (Sorivudine) cream, 3% in herpes zoster patients, Protocol ARYS-0502", 2006-2007.

99. Galderma: "A multi-center, randomized, double-blind, parallel-group study to demonstrate the efficacy and safety of Adapalene/Benzoyl Peroxide topical gel compared with Adapalene topical gel, 0.1%; Benzoyl Peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris, Protocol RD.06.SPR.18087", 2006-2007.

100. Medivir: "A randomized, double-blind, active-controlled, vehicle-controlled, subject initiated study comparing efficacy and safety of ME-609 versus acyclovir cream for recurrent herpes simplex labialis, Protocol 609-04", 2006-2008. **Principal Investigator**

101. Novartis: "A multicenter, randomized, double-blind study to compare the efficacy and safety of patient-initiated famciclovir 1000 mg b.i.d. x 1 day to valacyclovir 500 mg b.i.d. x 3 days in immunocompetent adults with recurrent genital herpes, Protocol CFAM810A2308", 2006-2008. **Principal Investigator**

102. Amgen, Inc.: "Observational Post-Marketing Safety Surveillance Registry of Enbrel (etanercept) for the Treatment of Psoriasis, Protocol 20040210", 2006-present.

103. Galderma: "Pharmacokinetics and Pharmacodynamics of Calcitriol Following Twice Daily Application of Calcitriol 3μg/g Ointment under Conditions of Maximal Use in Adolescents with Plaque Psoriasis. Protocol Number:RD.06.SPR.18102" 2006-2008.

104. Dow Pharmaceutical Sciences, Inc.: "A Multi-center, Randomized, Double-Blind, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene Lotion, 0.1% Compared with Vehicle Lotion in Subjects with Acne Vulgaris, Protocol RD.06.SPR.18113", 2007-2008.

105. PLIVA Research & Development Ltd: "A Randomized, Double-Blind, Multiple-site, Placebo Controlled, Parallel Design, Clinical Study to Evaluate the Bioequivalence of Adapalene Gel 0.1% (PLIVA Research & Development Ltd.) Compared to Differin (adapalene 0.1%) Topical Gel (Galderma Laboratories) in Patients with Acne Vulgaris, Protocol 70716202", 2007-2008. **Principal Investigator**

106. Glenmark Pharmaceuticals, Inc.: "A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multi-Site Clinical Study to Evaluate the Bioequivalence of Calcipotriene OIntment 0.005% (Glenmark Pharmaceuticals) to DOVONEX (calcipotriene ointment) 0.005% (Bristol Myers Squibb) in Patients with Moderate to Severe Plaque Psoriasis, Protocol GLK602", 2007-2008. **Principal Investigator**

107. BioAlliance Pharma SA: "A Randomised, Double-Blind, Single-dose, One-Day Early Administration, Multicentre Study comparing the Efficacy and Safety of Acyclovir

Lauriad 50 mg muco-adhesive buccal tablet to matching Placebo, in the Treatment of Herpes Labialis in Immunocompetent Patients" LIP Study (Lauriad Immunocompetent Patients Study), Protocol BA2005/21/02", 2007-2009. **Principal Investigator**

108. Astellas Pharma: "A Phase II Dose-Finding Study with ASP2151 in Subjects with Recurrent Episodes of Genital Herpes. Protocol 15L-CL-101", 2007-2009. **Principal Investigator**

109. Gilead Sciences, Inc.: "A Phase I, Randomized, Double-blind, Placebo-controlled Assessment of the Safety, Tolerability, and Activity of GS-9191 Ointment for the Treatment of External Genital and Perianal Warts Caused by Human Papilloma Virus Infection, Protocol GS-197-0101", 2007-2009.

110. Epiphany Biosciences, Inc.: "A randomized, double-blind, active-controlled, multi-center, parallel-group dose-ranging study assessing the safety and efficacy of EPB-348 versus valacyclovir among immunocompetent patients with an acute episode of herpes zoster, Protocol EPB348-0201", 2007-2009.

111. Hoffman-LaRoche: "A randomized, double-blind, placebo-controlled dose-ranging study to assess the safety, tolerability, pharmacokinetics and to explore the effect on clinical response and pharmacodynamics of RO5092888 in patients with moderate to severe chronic plaque psoriasis. Protocol No. NS20454", 2007-2009.

112. Abbott Laboratories: "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis, Protocol M06-890", 2007-2009. **Principal Investigator**

113. Abbott Laboratories: "A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study With ABT-874, Protocol M10-016", 2008-present. **Principal Investigator**

114. Abbott Laboratories: "A Phase 3, Multi-center, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects with Moderate to Severe chronic Plaque Psoriasis, Protocol M10-114", 2008-2009.

115. Abbott Laboratories: "Open-label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy, Protocol M10-238", 2008-2009. **Principal Investigator**

116. Abbott Laboratories: "A Phase 3, Multi-center, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and

Placebo in subjects with Moderate to Severe Chronic Plaque Psoriasis, Protocol M10-315", 2008-2009. **Principal Investigator**

117. Abbott Laboratories: "A controlled study of HUMIRA in subjects with chronic plaque psoriasis of the hands and/or feet, Protocol M10-405", 2008-2009.

118. Amgen, Inc.: "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in subjects with Moderate to Severe Plaque Psoriasis, Protocol 20080014", 2008-present. **Principal Investigator**

119. aRigen Pharmaceuticals, Inc.: "Phase II/III Multicenter, Double-Blind, Controlled Trial Comparing topical ARYS-01 Cream (3% Sorivudine), Oral Valaciclovir, and combination Topical ARYS-01 Cream/Oral Valaciclovir for the Treatment of Herpes Zoster in Immunocompetent Patients 18 Years of Age or Older, Protocol ARYS-0701", 2008-2009.

120. Galderma: "Efficacy and Safety comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel associated with Doxycycline Hyclate 100 mg Tablets versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Vehicle Gel associated with Doxycycline Hyclate 100 mg Tablets in the Treatment of Severe Acne Vulgaris., Protocol RD.03.SPR.29074", 2008-2009.

121. Pfizer Inc.: "A Phase 2B, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial Evaluating The Efficacy And Safety Of Dose Regimens With Oral CP-690,550 In The Treatment Of Subjects With Moderate To Severe Chronic Plaque Psoriasis, Protocol A3921047", 2008-2009. **Principal Investigator**

122. Galderma: "Efficacy and Safety comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Vehicle Gel as a 6-month Acne Maintenance Treatment, Protocol RD.03.SPR.29075", 2008-2009.

123. Graceway Pharmaceuticals: "A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Efficacy and Safety Study of Six Weeks of Treatment with Imiquimod Creams for Actinic Keratoses, Protocol GW01-0703", 2008-2009. **Principal Investigator**

124. Shionogi USA, Inc.: "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Two Doses of S-777469 (400 mg BID and 800 mg BID) in Patients with Atopic Dermatitis, Protocol 0721D1424", 2008-2009.

125. Stiefel Laboratories, Inc.: "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-ranging Study to Investigate the Efficacy and Safety of 4 Dose Regimens of Oral Albaconazole in Subjects with Distal Subungual Onychomycosis, Protocol W0027-10", 2008-2009.

126. Graceway Pharmaceuticals: "A Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year after Completion of Studies GW01-0702, GW01-0703, GW01-0704, and GW01-0705, Protocol GW01-0803", 2008-2009. **Principal Investigator**

127. Graceway Pharmaceuticals: "A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Imiquimod Creams in the Treatment of External Genital Warts, Protocol GW01-0805", 2008-2009.

128. Inhibitex, Inc.: "A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir in Patients with Herpes Zoster, Protocol INH-FV1-005", 2009-2010. **Principal Investigator**

129. Basilea Pharmaceutica International, Ltd.: "Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy, Protocol BAP01346", 2009-2010, **Principal Investigator**

130. Peplin Operations Pty Ltd: "A multi-center, Randomized, parallel group, double-blind, vehicle-controlled study to evaluate the Efficacy and safety of PEP005 (ingenol mebutate) Gel, 0.015% In patients with actinic keratoses ON the head (face or scalp) (REGION-IIa), Protocol PEP005-016", 2009-2010.

131. Taisho Pharmaceutical R&D Inc.: "A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy, Safety and Tolerability of TS-022 in Adults with a Diagnosis of Atopic Dermatitis (AD) with Moderate to Very Severe Pruritus, Protocol TS022-US201", 2009-2010.

132. Peplin: A 12 month, long-term follow-up study of patients with actinic keratosis on the head (face or scalp_ who have completed Day 57 in studies PEP005-016 or PEP005-025 (Region IIa and IIb), Protocol PEP005-030, 2009-2010.

133. Furiex, A Randomized, Controlled, Double-blind, Double-dummy, Multicenter Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared with Linezolid (Zyvox) for the Treatment of Complicated Skin and Skin Structure Infection, Protocol 32729463CSI2001, 2010-2010.

134. Nycomed US Inc: Antiviral and Immunomodulatory Effects of Veregen™ (sinecatechins ointment, 15%) in Patients with External Genital warts: An Investigator-Initiated, Open-Label, Mechanism of Action Study, Protocol AIR2010-044-1002-01, 2010-present.

135. Pfizer-Wyeth: Prevalence of Psoriatic Arthritis in Adults with Psoriasis: An Estimate from Dermatology Practice, Protocol 0881A6-4728-WW, 2010-present.

136. AiCuris GmbH & Co. KG: A double-blind randomized placebo controlled dose-finding

trial to investigate different doses of a new antiviral drug in subjects with genital HSV Type 2 infection, Protocol AIC-316-01-II-01, 2010-2011.

137. Pfizer: A Phase 3, Multi-site, Randomized, Mixed blind, Parallel-group Treatment Withdrawal and Re-treatment study of the efficacy and safety of 2 oral doses of CP-690,550 in subjects with moderate to severe chronic plaque psoriasis, Protocol A3921111, 2010-2013.

138. Pfizer: A phase 3, Multi-site, open-label study of the long term safety and tolerability of 2 oral doses of CP-690,550 in subjects with moderate to severe chronic plaque psoriasis, Protocol A3921061, 2010-Present. Principal Investigator

139. Novartis: A double blind, randomized, placebo controlled, multicenter, dose finding study of oral AEB071assesing Psoriasis Area and Severity Index (PASI) response as a function of dose and treatment duration (primary outcome) in patients with plaque psoriasis, Protocol CAEB071C2201, 2010-present.

140. LEO Pharma/TKL Research: Calcipotriol plus betamethasone dipropionate topical suspension compared to etamethasone dipropionate in the topical suspension vehicle, calcipotriol in the topical suspension vehicle and the topical suspension vehicle alone in psoriasis vulgaris, Protocol LEO80185 G23, 2010-present

141. Inhibitex: A Sub-study of the Pain Reduction Profile of 40-49 Year Old Herpes Zoster Subjects Treated With Open-label Valacyclovir Compared to Older Subjects in the Randomized, Double-Blind, Parallel-Group, Comparative Study, INH-FV1-005, Protocol INH-FV1-005-AGE, 2010-2011.

142. Galderma R& D: A Multicenter, Randomized, Vehicle-controlled, Double-blind, Parallel group Study of Efficacy and Safety of CD2027 3µg/g Topical Aerosol Applied Twice Daily for 8 Weeks in Subjects with Plaque-type Psoriasis, Protocol RD.06.SPR.18178, 2010-present

143. NerogesX: A multicenter randomized, double-blind, controlled study to evaluate safety, tolerability and preliminary efficacy of two capsaicin concentration variations of NGX-1998)10% or 20% w/w) in subjects with postherpetic Neuralgia (PHN), Protocol C204, 2010-Present. Principal Investigator

144. Amgen: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects with Moderate to Severe Plaque Psoriasis, Protocol 20070559, 2010-Present.

145. Amgen: A Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Psoriasis, Protocol 20090062, 2009-2010. Principal Investigator

146. Amgen: A Long-term assessment of the safety and efficacy of AMG 827 Subcutaneous treatment in subjects with Psoriasis, Protocol 20090403, 2010-Present. Principal Investigator

147. Amgen: A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis, Protocol 20080470. 2010-Present. Principal Investigator

148. Intendis: Double-blind, randomized, vehicle-controlled, multicenter, multinational, parallel-group study of the efficacy and safety of ZK 245186 ointment in concentrations of 0.01, 0.03 and 0.1% over 4 weeks in patients with Atopic Dermatitis (AD), Protocol 1403380, 2010-Present. Principal Investigator

149. Pfizer: " Prevalence of Psoriatic Arthritis in Adults with Psoriasis: An Estimate from Dermatology Practice, Protocol 0081A6-4728," 2010-2011.

150. Galderma: "A Multi-center, Randomized, Double- Blind, Placebo-Controlled, 3- Arm, Parallel Group Study Comparing the Efficacy and Safety of CD2475/101 40mg Tablets versus Placebo and Doxycyclin 100mg Capsules Once Daily in the Treatment of Inflammatory Lesions in Subjets with Acne Vulgaris, Protocol RD.06.SPR.18195,"2010-2011.

151. Inhibitex: " A Phase II, Multicenter, Randomized, Double- Blind, Parallel- Group, Comparative Study of FV-100 vs. Valacyclovir in Patients with Herpes Zoster, Protocol INH-FV1-005, " 2010-2011.

152. Celgene: " A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis, Protocol CC-10004- PSOR-009,"2011- Present

153. Pfizer: A phase 3, multi-site, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of 2 oral doses of CP-690,550 in subjects with moderate to severe chronic plaque psoriasis, Protocol A3921078, 2011-Present

154. Celgene: A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who have not been previously treated with disease-modifying antirheumatic drugs, Protocol CC-10004-PSA-005, 2011-Present.

155. Celgene. " A Phase 3 Multicenter, Randomized, Double- Blind, Placebo- Controlled, Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis , Protocol CC-10004- PSOR-008," 2012- Present.

156. Maruho: " A Randomized, Placebo – Controlled, Double- Blind, Parallel Group, Multi-

Center Phase IIb Dose Finding Study of M518101 in Plaque Psoriasis Patients, Protocol M51801-US01," 2011-2012.

157. Novartis:" A Randomized, Double- blind, Placebo controlled, Multi- center Study of Subcutaneous Secukinumab to Demonstrate Efficacy after Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long- Term Efficacy up to One Year in Subjects with Moderate to Severe Chronic Plaque Type Psoriasis Lesions, Protocol CC-10004-PSA-004," 2011- Present.

158. Celgene: " A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis and a Qualifying Psoriasis Lesions, Protocol CC-10004-PSA-004," 2011-Present.

159. Intendis: " ADouble-Blind, Randomized,Vehicle-Controlled, Multi-Center, Multi-National, Parallel-Group Study of the Efficacy and Safety of ZK 245186 Ointment in Concentrations of 0.01, 0.03 and 0.1% Over 4 weeks in Patients with Atopic Dermatitis (AD), Protocol 1403380," 2011-2012.

160. Centocor: "A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis, Protocol CNTO1959PSO2001," 2011-2013.

161. Pfizer: "A Phase 3, Multi-site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of 2 Oral Doses of CP-650,550 in Subjects With Moderate to Severe Chronic Plaque Psoriasis, Protocol A3921078," 2011-2012.

162. Celgene: " A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Two Doses of Apremilast (CC-1004) in Subjects with Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-Modifying AntiRheumatic Drugs, Protocol CC-10004-PSA-005," 2011-Present.

163. Celgene: "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Two Doses Of Apremilast (CC-10004) In Subjects With Active Psoriatic Arthritis, Protocol CC-10004-PSA-002" 2011-2013

164. Nycomed: "Antiviral and Immunomodulatory Effects of Veregen (sinecatechins ointment, 15%) in Patients with External Genital Warts: An Investigator-Initiated, Open-Label, Mechanism of Action Study, Protocol AIR2010-44-1002-01 MOA," 2011-2012.

165. Galderma: "A Phase 3 Randomized, Double-Blind, 12 Week Vehicle-Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects with Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long-Term Safety of CD5024 1% Cream Versus

Azelaic Acid 15 % gel, Protocol RD.06.SPR.1870," 2011-2012.

166. Galderma: "A Phase 3 Randomized, Double-Blind, 12 Week Vehicle-Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects with Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long-Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel, Protocol RD. 06. SPR.18171," 2011-2013.

167. Amgen: "An Open Label Study to Evaluate the Efficacy of Etancercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab, Protocol 20101145," 2012-Present.

168. Apo-Pharma: "A 12-week Randomized, Double-blind, Placebo-controlled, Multicenter, Multiple Sequential Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Apo805K1 in Subjects with Moderate to Severe Chronic Plaque Psoriasis, Protocol AP03-2010," 2012

169. Pfizer: "A Phase 3, Multi-site, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of 2 Oral Doses of CP-690,550 in Subjects With Moderate to Severe Chronic Plaque Psoriasis, Protocol A3921079," 2012-2013.

170. Novum: "A Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Study Comparing Metronidazole Topical Gel 1% (Taro Pharmaceutical Industries, Ltd.) to METROGEL (metronidazole gel) 1% (Galderma) in the Treatment of Moderate to Severe Rosacea, Protocol 71142601," 2012.

171. Idera: "A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis, Protocol 3100-202" 2012.

172. Medicis: "A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis, Protocol MP-1001-01" 2012.

173. Leo Pharma: "A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp, Protocol LP0041-21" 2012-2013.

174. Eli Lilly: "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis, Protocol I1F-MC-RHBA" 2012-Present.

175. Amgen: "A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis, Protocol 20120104" 2012-2013.

176. Genocea: "A Phase I/IIa, Randomized, Double-blind, Dose-ranging, Placebo-controlled

Study of the Safety and Immunogenicity of a HSV-2 Vaccine Containing Matrix M-2 Adjuvant in Individuals With Documented Genital HSV-2 Genital Infection, Protocol GEN-003-001" 2012-2016

177. Agenus: "A Phase 2a Multicenter, Double-blinded, Randomized Trial to Evaluate The Effect of HerpV on Viral Shedding in Adults With Recurrent Genital Herpes, Protocol C-400-02" 2012-Present.

178. Galderma: "A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris, Protocol RD.06.SPR.18223" 2012-2013.

179. Asubio: "A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis, Protocol ASBI 704" 2012-2014.

180. Merck: "A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis, Protocol MK-3222-010" 2013-2019.

181. Bayer: "A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea, Protocol 1401846" 2013-2014.

182. Novartis: "Phase II Randomized Double Blinded Placebo Controlled, Multiple-dose Regimen Study to Assess the Rate of Histological Clearance and Effect on Molecular Pathways as Well as on Biomarkers of 12 Months Secukinumab 300 mg s.c. Treated Patients With Chronic Plaque-type Psoriasis, Protocol CAIN457A2223" 2013-2015.

183. Allergan: "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of a Single Treatment of AGN-214868 in Patients With Postherpetic Neuralgia, Protocol AGN 214868-007" 2013-2014.

184. Maruho: "A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis, Protocol M518101-US02" 2013-2015.

185. Novartis: "A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis, Protocol CAIN457A2308" 2013-Present.

186. Novartis: "A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long-term Efficacy, Safety, and Tolerability up to 2 Years in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab, Protocol CAIN457A2302E1" 2013-Present.

187. Pfizer: "An Exploratory Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess Mechanism Of Action (MOA) Of CP-690,550 In The Skin When Administered Orally At 10 Mg Twice Daily (BID) For 12 Weeks In Subjects With Moderate To Severe Chronic Plaque Psoriasis, Protocol A3921147" 2013-Present.

188. Regeneron: "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of REGN668 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis, Protocol R668-AD-1021" 2013-2014.

189. Amgen: "A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis, Protocol 20120103" 2013-Present.

190. Promius Pharma: "A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of Betamethasone Dipropionate Spray 0.05% in the Treatment of Moderate Plaque Psoriasis, Protocol BDS1206" 2013-Present.

191. Leo Pharma: "Safety and efficacy of escalating doses of ingenol mebutate once daily for two or three consecutive days when used on full face, full balding scalp or approximately 250 cm2 on the chest in subjects with actinic keratosis, Protocol LP0105-1012" 2013-Present.

192. Leo Pharma: "An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life, Protocol APPEAL" 2013.

193. Vical: "A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults, Protocol HSV2-101" 2013-2016.

194. Allergan: "A Safety and Efficacy Study to Compare Dapsone Dermal Gel with Vehicle Control in Patients with Acne Vulgaris, Protocol 225678-007" 2013-2014.

195. Regeneron: "An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials, Protocol R668-AD-1225" 2013-Present.

196. Promius Pharma: "A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety of Betamethasone Dipropionate Spray 0.05% versus Diprolene® (augmented betamethasone dipropionate) Lotion 0.05% and the Efficacy of Betamethasone Dipropionate Spray 0.05% versus Vehicle Spray in the Treatment of Moderate Plaque Psoriasis, Protocol BDS1205" 2014-Present.

197. Novartis: "A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Longterm Efficacy up to 80 Weeks in Subjects With Moderate to Severe Nail Psoriasis, Protocol CAIN457A2313" 2014-Present.

198. Novartis: "A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque psoriasis, Protocol CAIN457A2317" 2014-Present.

199. Amgen: "A Comparison of Psoriasis Symptom Severity and Health-Related Quality of Life in Patients With Clear and Almost Clear Levels of Skin Improvement, Protocol 20130127 (HRA 1889A)" 2014-Present.

200. Merck: "A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222 / MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis, Protocol MK-3222-011" 2014-2020.

201. Boehringer-Ingelheim: "A 48 weeks study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator controlled (ustekinumab), double-blind within dose groups of BI 655066), Protocol 1311.2" 2014-2015.

202. Promius Pharma: "A Randomized, Parallel, Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing with Betamethasone Dipropionate Spray 0.05% versus Diprolene® (augmented betamethasone dipropionate) Lotion 0.05% in Subjects with Moderate to Severe Plaque Psoriasis, Protocol BDS1307" 2014.

203. Amgen: "A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis who Achieve Complete Clearance on Biologics, Protocol 20120363" 2014-Present.

204. Genocea: "A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection, Protocol GEN-003-002" 2014-2016.

205. Regeneron: "A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab, Protocol R668-AD-1314" 2014-2015.

206. LEO Pharma: "Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis, Protocol LP0084-1014" 2014-2015.

207. Otsuka: "A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis, Protocol 271-12-205" 2014-Present.

208. Anacor: "A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis, Protocol AN2728-AD-302" 2014-2015.

209. Coherus: "A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 versus Enbrel in Subjects with Chronic Plaque Psoriasis (RaPsOdy), Protocol CHS-0214-04" 2014.

210. Janssen: "Exploratory Genetic Study in Subjects with Moderate to Severe Psoriasis, Protocol NOCOMPOUNDPSO0001" 2014.

211. Sandoz: "A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humira® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis, Protocol GP17-301" 2014-2016.

212. Actavis: "A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris, Protocol SC1401" 2014-Present.

213. Janssen: "Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis, Protocol CNTO1959PSO3001" 2014-Present.

214. Janssen: "A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment, Protocol CNTO1959PSO3002" 2014-Present.

215. Janssen: "A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab, Protocol CNTO1959PSO3003" 2014-Present.

216. Dermira: "A Phase 3 Multicenter, Randomized, Double Blind, Parallel Group Study Followed by Dose Blind Period and Open Label Follow Up to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis, Protocol PS0005" 2014-Present.

217. Pfizer: "A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Efficacy of PF-04965842 in Subjects with Moderate to Severe Psoriasis, Protocol B7451005" 2014-2016.

218. Polynoma: "A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence, Protocol POL-103A" 2015-Present.

219. Regeneron: "A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis, Protocol R668-AD-1416" 2015-Present.

220. Boehringer Ingelheim: "An Open Label Extension Trial Assessing the Safety and Efficacy of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis Protocol 1311.13" 2015-Present.

221. Medimmune: "A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis, Protocol D2213C00001" 2015-2016.

222. Tolmar: "A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multicenter Study Comparing TOLMAR Calcipotriene Ointment, 0.005% to Reference Listed Drug in the Treatment of Plaque Psoriasis, Protocol TOL2707A" 2015-Present.

223. Genocea: "Rollover Trial for Placebo Subjects Previously Enrolled into GEN-003-002 - A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects with Genital HSV-2 Infection, Protocol GEN-003-002a" 2015-Present.

224. LEO Pharma: "Safety of LEO 43204 0.018%, 0.037% and 0.1% for actinic keratosis applied once daily for three consecutive days on face/chest, scalp and trunk/extremities, respectively, Protocol LP0084-1148" 2015-Present.

225. LEO Pharma: "Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic

Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest, Protocol LP0105-1032" 2015-Present.

226. Actavis: "A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris, Protocol SC1403" 2015-Present.

227. Dermira: "A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging, Study of DRM01B Topical Gel in Subjects with Acne Vulgaris, Protocol DRM01B-ACN02" 2015-Present.

228. Novartis: "A randomized, vehicle controlled, active comparator, parallel group study to evaluate efficacy, safety, and tolerability of topical LFX453 formulations in patients with external genital warts (EGWs), Protocol CLFX453X2202" 2015-Present.

229. LEO Pharma: "Efficacy and safety of LEO 43204 in field treatment of Actinic keratosis on face or chest including 12 month follow- up, Protocol LP0084-1193"2015-Present.

230. LEO Pharma: " Efficacy and safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp including 12- month follow- up, Protocol LP0084-1195" 2015- Present.

231. Cutanea: " A Phase 2, Randomized, Double- Blind, Vehicle- Controlled, Parallel Group Multicenter Study to Evaluate the Safety and Efficacy of CLS001 Topical Gel versus Vehicle Applied Once Daily for 12 Weeks to Female Subjects with Moderate to Severe Acne Vulgaris, Protocol CLS001-CO-PR-009" 2015- Present.

232. Hologic: "Clinical Evaluation of the Aptima Herpes Simplex Viruses 1 & 2 Assay on the Panther System in Swab Specimens From Symptomatic Subjects Presenting With a Suspected Herpes Lesion(s)" 2015- Present.

233. Coherus: " A Double- Blind, Randomized, Parallel- Group, Active- Control Study to Compare the Efficacy and Safety of CHS- 1420 Versus Humira in Subjects with Chronic Plaque Psoriasis, Protocol CHS-1420-02" 2015- Present.

234. Contravir: " A Multicenter, Randomized, Double- Blind, Parallel- Group, Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post- Herpetic Neuralgia and Treatment of Acute Herpes Zoster- Associated Pain, Protocol CTRV-FV-2-007" 2015-Present.

235. Novan: "A Phase 2 Multi-Center, Double- Blind, Randomized, Vehicle- Controlled, Ascending Dose Study assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects with External Genital Warts and Perianal Warts, 2015- Present.

236. Valeant: " A Pase 3, Multi- Center, Randomized, Double- Blind, Vehicle- Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris, Protocol V01-121A-301"

2015- Present.

237. Eli Lilly: " A Multicenter, Randomized, Double- Blind Study Comparing the Efficacy and Safety of Ixekizumab dosing Regimens in Patients with Moderate- to – Severe Plaque Psoriasis, Protocol I1F-MC- RHBP(a)" 2015- Present.

238. Galderma: " A Multicenter, Randomized, Double- Blind, Parallel- Group Vehicle Controlled Study To Compare The Efficacy And Safety of CD5789 Cream Versus Vehicle Cream In Subjects With Acne Vulgaris, Protocol RD.06.SPR.18252" 2015- Present.

239. GlaxoSmithKline: "Study 203121: A Randomized, Blinded, Vehicle- Controlled, Dose-Finding Study of GSK 2894512 Cream for the Treatment of Atopic Dermatitis" 2015- Present.

240. GlaxoSmithKline: "Study 203120: A Randomized, Blinded, Vehicle- Controlled, Dose-Finding Study of GSK 2894512 Cream for the Treatment of Plaque Psoriasis" 2015- Present.

241. Vitae Pharmaceuticals: A Randomized, double- Blind, Placebo- controlled Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Health volunteers and Proof-of- Concept in Psoriatic Patients" 2015- 2016

242. Valeant: "A Phase 3, Multicenter, Open Label Study to Evaluate the Long- Term Safety of IDP- 118 Lotion in the Treatment of Plaque Psoriasis, Protocol V01-118A-303" 2015- Present.

243. Valeant: "A Phase 3, Multicenter, Double- Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis, Protocol V01-118A-302" 2015- Present.

244. Lilly Chorus: " A Randomized, Double- Blind, Placebo- Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients with Moderate- to- Severe Atopic Dermatitis, Protocol I4V-MC-JAHG (a)" 2016-Present.

245. Boehringer Ingelheim: "BI 655066 versus placebo In a Multicenter randomized double blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re- treatment, Protocol BIPI 1311.4" 2016- Present.

246. Boehringer Ingelheim: "BI 655066 versus Ustekinumab and placebo comparators in a randomized double blind trials for Maintenance use in Moderate to severe plaquetype psoriasis, Protocol BIPI 1311.3" 2016- Present.

247. Novartis: A randomized, double- blind, placebo- controlled, parallel- group, multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometaboloic biomarkers after 12 weeks of treatment, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult subjects with moderate to severe chronic plaque- type psoriasis, Protocol CAIN457AUS02" 2016- Present.

248. Cutanea: A phase 3 Open- Label Extension Study to Evaluate the Long- Term Safety of Omiganan Topical Gel in subjects with Rosacea, Protocol CLS001-CO-PR-006

249. Menlo Therapeutics: " A Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy, Safety, And Tolerability Of Serlopitant For The Treatment Of Pruritus In Adults With Plaque Psoriasis" Protocol: MTI-109, 2017-2020.

250. Menlo Therapeutics: "A Randomized, Double-Blind, Placebocontrolled Study Of The Efficacy, Safety, And Tolerability Of Serlopitant For The Treatment Of Pruritus In Adults With Prurigo Nodularis" Protocol: MTI-105, 2018-2020. Principal Investigator

251. Menlo Therapeutics: "An Open-Label Long-Term Safety Study Of Serlopitant For The Treatment Of Pruritus" Protocol: MTI-107, 2018-2020. Principal Investigator

252. Novartis: "A 16-week randomized, open-label, multicenter study to assess the superiority of secukinumab over guselkumab in the complete treatment of ustekinumab-resistant psoriatic plaques – ARROW", Protocol: CAIN457A2403 (240099 ARROW), 2018-2019.

253. UCB Biopharma: "A Phase 3, Multicenter, Randomized, Double-Blind Study With An Active-Controlled Initial Treatment Period Followed By A Dose-Blind Maintenance Treatment Period To Evaluate The Efficacy And Safety Of Bimekizumab In Adult Subjects With Moderate To Severe Chronic Plaque Psoriasis" Protocol: PS0008, 2018-2020. Principal Investigator

254. UCB Biopharma: "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- And Active Comparator-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of Bimekizumab In Adult Subjects With Moderate To Severe Chronic Plaque Psoriasis" Protocol: PS0009, 2018-2020. Principal Investigator

255. AbbVie: "A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy" Protocol M16-766, 2018-2020. Principal Investigator

256. Dr. Reddy's Laboratories: "A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-Week Study To Assess The Efficacy And Safety Of PPC-06 (Tepilamide Fumarate) Extended Release Tablets In Subjects With Moderate-To-Severe Plaque Psoriasis" Protocol: PPC-06-CD-004, 2018-Present.

257. Arcutis: "A Phase 2, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Adult Subjects with Chronic Plaque Psoriasis who have Completed Preceding Study ARQ-151-201 Phase 2 Randomized Controlled Trial (Cohort 1) and non-ARQ-151-201 Subjects (Cohort 2)" Protocol: ARQ-151-202, 2018-Present. Principal Investigator

258. Novartis: "Phase 3b; A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study To Demonstrate The Efficacy, Safety And Tolerability Of Subcutaneous Secukinumab Injections With 2 mL Auto-Injectors (300 mg) In Adult Subjects With Moderate To Severe Plaque Psoriasis – MATURE" Protocol: AIN457A2325, 2018-Present.

259. Genentech (PPD): "A Phase II, Randomized, Double Blind, Placebo Controlled Multicenter Study To Assess The Efficacy And Safety Of MSTT1041A In Patients With Moderate To Severe Atopic Dermatitis", Protocol: GS40965, 2018-2020.

260. UCB Biopharma: "A Multicenter, Open-Label Study To Assess The Long-Term Safety, Tolerability, And Efficacy Of Bimekizumab In Adult Subjects With Moderate To Severe Chronic Plaque Psoriasis", Protocol: PS0014, 2018-Present. **Principal Investigator**

261. Eli Lilly and IQVIA: "Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe Alopecia Areata", Protocol: I4V-MC-JAHO, 2018-Present. **Principal Investigator**

262. Eli Lilly and IQVIA: "A 24-Week Multicenter, Randomized, Double-Blind, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients with Moderate to Severe Plague Psoriasis", Protocol: I1F-MC-RHCR, 2018-2020. **Principal Investigator**

263. Celgene: "A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Genital Psoriasis." Protocol: CC-10004-PSOR-025, 2018-Present.

264. "IM011046: A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis." 2018-2020. **Principal Investigator.**

265. AbbVie: "Moderate to Severe Atopic Dermatitis: Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects", Protocol: M16-047, 2018-Present. **Principal Investigator**

266. Pfizer (ICON): "Phase 3 Atopic Dermatitis Study in Adults on Background Topical Therapy with Moderate to Severe AD" Protocol: B7451029 – 9002/0563, 2018-2020. **Principal Investigator**

267. Pfizer (ICON): "A Phase 3 Randomized, Double-Blind, Multi-Center Long Term Extension Study Investigating The Efficacy And Safety Of PF-04965842 With Or Without Topical Medications, Administered To Subjects Aged 12 Years And Older, With Moderate To Severe Atopic Dermatitis" Protocol: B7451015-9002/0535, 2018-Present. **Principal Investigator.**

268. Incyte (PPD): "A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis" Protocol: INCB 18424-304, 2018-Present.

269. SGT-65-05: A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S6G5T-3 in the Treatment of Acne Vulgaris. 2019-2020.**Principal Investigator**

270. AbbVie: "A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis", Protocol: M16-813, 2019-Present.

271. Jiangsu Hengrui Medicine Co., Ltd.(Parexel): "A Multi-Center, Randomized, Double-blind,

Placebo-controlled, Multi-Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics , and Efficacy of SHR-1314 with Expanded Dose Finding in Subjects with Moderate-to-severe Plaque Psoriasis", Protocol: SHR-1314-A201, 2019-2020. **Principal Investigator**

272. Aclaris: "A Phase 3 Open Label Safety Study Of A-101 Topical Solution For The Treatment Of Common Warts" Protocol: A-101-WART-303, 2019-2020.

273. "A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm Study of the Anti-Pruritic Efficacy and Safety of Nalbuphine ER Tablets in Prurigo Nodularis." Protocol: TR11-43180001 (TREVI PRISM). 2019-Present. **Principal Investigator.**

274. Celgene: "A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of The Efficacy And Safety Of Apremilast (CC-10004) In Subjects With Mild To Moderate Plaque Psoriasis" Protocol: CC-10004-PSOR-022, 2019-2020.

275. Pfizer (ICON): "Phase 2; The primary objective of the study is to provide data on efficacy, safety, tolerability and PK of multiple topical formulation concentrations of PF-06700841 topical cream in the treatment of mild-to-moderate atopic dermatitis (AD)." Protcol: B7931022, 2019-2020. **Principal Investigator**

276. Pfizer (ICON): "A Phase 2B, Randomized, Double Blind, Vehicle-Controlled, Parallel-Group, Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream Applied Once or Twice Daily for 12 Weeks in Participants with Mild to Moderate Chronic Plaque Psoriasis." Protocol: B7931023, 2019-Present. **Principal Investigator**

277. Sun Pharma (IQVIA/ Cu-Tech): "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp", Protocol: TILD-18-20, 2019-Present. **Principal Investigator**

278. Galapagos (Novella Clinical): "A randomized, double-blind, placebo-controlled, multicenter Phase 2 study to evaluate the safety and tolerability of subcutaneous MOR106 administered concomitantly with topical corticosteroids for eight weeks, in adult subjects with moderate to severe atopic dermatitis." Protocol: MOR106-CL-204, 2019-2020. **Principal Investigator**

279. Bristol-Myers Squibb: "An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis," Protocol: BMS IM011075 extension, 2019-Present. **Principal Investigator**

280. Dermavant (Novella/ IQVIQ Biotech): "A Phase 3 Efficacy and Safety Study of Tapinarof Cream 1% vs Vehicle for the Treatment of Adult Plaque Psoriasis" Protocol: DMVT-505-3002, 2019-2020. **Principal Investigator**

281. Dermavant (Novella/ IQVIQ Biotech): "A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% for the Treatment of Plaque Psoriasis in Adults E140", Protocol: DMVT-505-3003, 2019-Present. **Principal Investigator**

282. Pfizer (Parexel): "A Phase 3, Randomized, Double-Blind, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction with Crisaborole

Ointment, 2%, Once Daily Over 52 Weeks in Pediatric and Adult Participants (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis, who Responded to Twice Daily Crisaborole Ointment, 2%, Treatment." Protocol: C3291035 (244373), 2019-Present. Principal Investigator

283. Galderma (Syneos Health): "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis", Protocol: RD.03.SPR.118169 (NEMO program), 2019-Present.

284. Galderma (Syneos Health): "RD.06.SPR.118163A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis." 2020-Present.

285. Galderma (Syneos Health): RD.06.SPR.118380 "A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Subjects with Moderate-to-Severe Atopic Dermatitis Treated with Nemolizumab." 2020-Present. Principal Investigator

286. "Protocol M17-238 A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Subjects with Chronic Plaque Psoriasis." 2020-Present.

287. "Phase 2; Proof of Concept trial in moderate-to-severe Inflammatory Acne patients, testing an oral drug (LYS006) vs placebo." CLYS006X12201. 2020-Present. Principal Investigator

288. "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)."TILD-19-07. 2020-Present.

289. "A Randomized, Double-Bind, Placebo-Controlled Study To Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis." Protocol: RD.06.SPR.203065 (Olympia). 2020-Present.

290. "An open-label, single arm study is 52 weeks in duration for male or female adolescents (≥12 years to 17 years, and weighing ≥40 kg). The objective is to evaluate the safety of Lebrikizumab in adolescent patients (≥12 to 17 years weighing ≥40 kg) with moderate-to-severe AD." Protocol: DRM06-AD17 (J2T-DM-KGAE) ADore program. 2020-Present. Principal Investigator

291.

VACCINE DEVELOPMENT AND TESTING

292. Chiron Corp.: "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy of an HSV Vaccine Composed of Recombinant Herpes Simplex Virus Type 2 (HSV-2) Subunit Antigens Combined with MF 59 Adjuvant Emulsion when Given to HSV-2 Seronegative Monogamous Sex Partners of Persons with Genital Herpes Type 2, Protocol V5P16" 1994-1996.

293. Chiron Corp.: "A Phase III, Double Blind, Randomized, Parallel Design, Multi Center, Lot-to-Lot Consistency Study of the Safety, Tolerability, and Immunogenicity of an HSV Vaccine Composed of Recombinant Herpes Simplex Virus Type 2 (HSV-2) Subunit Antigens Combined with MF59 Adjuvant Emulsion When Given to Healthy HSV-2 Seronegative Adults, Protocol V5P17" 1995-1996.

294. Chiron Corp.: "A Phase III, Double Blind, Randomized, Placebo-Controlled, Parallel Multi Center Study of the Efficacy of a Fourth Immunization with an HSV Vaccine Composed of Combined Recombinant Herpes Simplex Virus Type 2 Subunit Antigens Combined with MF59 Adjuvant Emulsion when given to Previously Immunized Subjects in Protocol V5P16, Protocol V5P12" 1995-1997.

295. Chiron Corp.: "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of the Efficacy of an HSV Vaccine Composed of Recombinant Herpes Simplex Virus Type 2 (HSV-2) Subunit Antigens Combined with MF 59 Adjuvant Emulsion When Given to HSV-2 Seronegative Adults at High Risk for Acquisition of Sexually Transmitted Diseases, Protocol V5P15" 1994-1996.

296. SmithKline Beecham Biologicals: "A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) with MPL to Prevent Genital Herpes Disease in Healthy Consorts of Subjects with Genital Herpes Disease, Protocol 007" 1994-1998.

297. SmithKline Beecham Biologicals: "A Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) with MPL and its Efficacy to Prevent Genital Herpes Disease in HSV Positive or Negative Consorts of Subjects with Genital Herpes Disease, Protocol 017" 1995-1998.

298. SmithKline Beecham Biologicals: "A Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) with MPL in HSV Seropositive or Seronegative Subjects Without Genital Herpes Disease, Protocol 016" 1995-1997.

299. VaxGen, Inc.: "A Phase III Trial to Determine the Efficacy of Bivalent AIDSVAX B/B Vaccine in Adults at Risk of Sexually Transmitted HIV-I Infection in North America" 1998-2003.

300. Merck & Company, Inc.: "Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 2-dose Regimen of High Titered Process Upgrade Varicella Vaccine (PUVV) in subjects ≥13 Years of Age" 1999-2001.

301. Glaxo Wellcome, Inc.: "A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of TA-HSV(GW419458X) Vaccine for the Treatment of Recurrent Herpes Genitalis" 1999-2001.

302. Med Immune: "A Phase II Double-Blind, Randomized, Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, in Healthy Adult Female Volunteers, Protocol MI-CP057" 1999-2001.

303. Med Immune: "A Phase I Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-like Particle Vaccine against Human Papillomavirus (HPV) Types 16 and 18, in Healthy Adult Female Volunteers who are HPV-16 or HPV-18 DNA Positive, Protocol MI-CP058" 1999-2001.

304. SmithKline Beecham Biologicals: "A Multicenter, Epidemiology Study to Evaluate the Prevalence of Human Papillomavirus (HPV) Infections in Adolescent and Adult Females in North America and Brazil, Protocol HPV-106" 2000-2001.

305. SmithKline Beecham Biologicals: "A Double-Blind Placebo-controlled, Randomised, Pilot Phase IIB Study of the Efficacy of an HPV-16/18 VLP vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Healthy Adolescent and Young Adult Women in North America and Brazil, Protocol HPV-001" 2001-2003.

306. Merck & Co., Inc: "A Double-Blind Placebo Controlled, Randomized Study to Evaluate Safety, Tolerability and Immunogenicity After One and Two Doses of PHN/Zoster Vaccine, Protocol 007-00" 2001-2005.

307. GlaxoSmithKline': "Open Study to Further Evaluate the Safety, Reactogenicity, and Immunogenicity of GlaxoSmithKline Biologicals' Prophylactic Herpes Simplex Candidate Vaccine with gD-alum-MPL in HSV-1 and HSV-2 Seronegative (HSV 1-/2-) Women Who Previously Received Either, Alum-MPL or Alum as Placebo During One of GlaxoSmithKline Biologicals' Phase III Studies 208141/005 (HSV-007), 208141/016 (HSV-016) or 208141/017 (HSV-017), Protocol 038" 2002-2004.

308. Merck & Co., Inc.: "Evaluation of the Safety and Tolerability of a Higher Potency Dose of Varicella Zoster Vaccine Live (Oka/Merck) Among Adults 50 Years of Age and Older, Protocol 009-00", 2004.

309. National Institutes of Health/GlaxoSmithKline Biologicals: "A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women who are HSV-1 and -2 Seronegative. Protocol 208141/039 (HSV-039)" 2003-2010. **Principal Investigator**

310. PowderMed Ltd: "A phase 1 research study to investigate the safety, tolerability and immunogenicity of a DNA therapeudic vaccine for the herpes simplex type 2 virus. Individuals will be followed up at various intervals and for approximately 7-8 months, PJ HSV-001", 2004-2007.

311. GlaxoSmithKline: "A phase IIb, blinded, multi-center, long-term follow-up study of the efficacy of candidate HPV-16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in adolescent and young adult women in North America and Brazil vaccinated in 001, Protocol HPV 580299/007", 2004-2008.

312. GlaxoSmithKline: "A phase III, double-blind, randomized, controlled, multi-center study to evaluate the efficacy of GlaxoSmithKline Biologicals' HPV-16/18 VLP/AS04 vaccine compared to hepatitis A vaccine as control in prevention of persistent HPV-16 or HPV-18 cervical infection and cervical neoplasia, administered intramuscularly according to a 0, 1, 6 month schedule in healthy females 15-25 years of age, Protocol HPV 580299/008" 2004-2009. **Principal Investigator**

313. Merck & Co., Inc: "A Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase II Proof-of-Concept Study to Evaluate the Safety and Efficacy of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd5 HIV-1 gag/pol/nef) in Adults at High Risk of HIV-1 Infection. Protocol V520-023" 2005-2009. **Principal Investigator**

314. Merck & Co., Inc.: "A Phase III Clinical Trial to Study the Safety, Tolerability and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in subjects With a History of Herpes Zoster, Protocol V211-014", 2006-2008.

315. Merck & Co., Inc: "A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥ 60 Years of Age. V211-020-00" 2007-2010. **Principal Investigator**

316. Merck & Co., Inc.: "A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerabililty of ZOSTAVAX in subjects 50 to 59 Years of Age, Protocol V211-022", 2007-2010.

317. Merck & Co., Inc.: "A Double-blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate Biomarkers of Immunity to Varicella Zoster Virus Following Immunization with V212/Heat-Treated Varicella-Zoster Virus (VAV) Vaccine or with ZOSTAVAX™ in Healthy Volunteers, Protocol V212-003", 2009-2010.

318. GlaxoSmithKline: "Safety study of GSK Biologicals' human papillomavirus vaccine (GSK580299) in female American and Canadian subjects who had received control vaccine in study 580299/008, Protocol HPV 111955/057)", 2009-2010. **Principal Investigator**

COMMITTEE RESPONSIBILITIES:

Medical Advisor: Houston area chapter of Herpes Resource Center

MENTORSHIP OF POST-DOCTORAL FELLOWS AT Center for Clinical Studies:

Julie Martin, M.D.	2009-present
Katie Morrison, M.D.	2009-present
Christopher Willison, M.D.	2009-present

Parisa Ravanfar, M.D.	2008-2009
Rosella Creed, M.D.	2008-2009
Anita Satyprakash, M.D.	2008-2009
Anne Marie Tremaine, M.D.	2007-2008
Brenda Bartlett, M.D.	2007-2009
Aron Gewirtzman, M.D.	2007-2008
Anita Arora, M.D.	2006-2007
Wendy Madkan, M.D.	2005-2006
Julie Brantley, M.D.	2005-2006
Katie Pang, M.D.	2003-2004
Jashin Wu, M.D.	2003-2004
Karan Sra, M.D.	2004-2005
Vandana Madkan, M.D.	2005-2007
Julie Brantley, M.D.	2005-2006
Anita Arora, M.D.	2006-2007
Anne Marie Tremaine, M.D.	2007-2008
Aron Gewirtzman, M.D.	2007-2008
Brenda Bartlett, M.D.	2007-2009
Anita Satyaprakash, M.D.	2008-2009
Rosella Creed, M.D.	2008-2009
Parisa Ravanfar, M.D.	2008-2009
Katie Morrison, M.D.	2009-2010
Beau Willison, M.D.	2009-2010
Whitney Lapolla, M.D.	2010-2011
Catherine Digiorgio, M.D.	2010-2011
George Magel, M.D.	2010-2011
Kassie Haitz, M.D.	2010-2011

MENTORSHIP OF POST-DOCTORAL FELLOWS AT UTMB:

Gisela Torres, M.D.	2002-2003
Mathijs Brentjens, M.D.	2001-2002
Kimberly Yeung-Yue, M.D.	2001-2002
Melody Vander Straten, M.D.	1999–2001
Tricia Brown, M.D.	1999-2000
Tanya Evans, M.D.	1997-1999
Komal Chopra, M.D.	1996-1997
Kathleen Herne, M.D.	1994-1996
Monica McCrary, M.D.	1995-1996
Richard Cirelli, M.D.	1993-1994
Paul Rockley, M.D.,	1992-1994

MEMBERSHIP IN SCIENTIFIC SOCIETIES:

Texas Medical Association
International Society of Dermatopathology
International Society for Antiviral Research
American Academy of Dermatology (Affiliate Member)

BOARD CERTIFICATION:

American Board of Pathology

PUBLICATIONS:

1. Tyring, S. and **Lee, P.**: Hemorrhagic bullae associated with *Vibrio vulnificus* septicemia. Arch. Dermatol. 122:818-820; 1986.

2. Soong, V., **Lee, P.**, Sams, W.M. and Tyring, S.: Fatal malignant melanoma associated with a completely regressed primary melanoma in a patient with cutaneous T cell lymphoma. Arch. Dermatol. 123:1270-1272; 1987.

3. Tyring, S.K., **Lee**, P.C., Omura, E., Green, L.K. and Merot, Y: Recurrent metastatic cutaneous neuroendocrine (Merkel cell) carcinoma mimicking angiosarcoma. Arch. Dermatol. 123:1368-1370; 1987.

4. Jones, C., Tyring, S., **Lee, P.** and Fine, J.D.: Development of neuroendocrine ("Merkel cell") carcinoma mixed with squamous cell carcinoma in erthema ab igne. Arch. Dermatol. 124:110-113; 1988.

5. Tyring, S. Jones, C., **Lee, P.** and Fine, J.D.: Development of verrucous plaques and gross hematuria in advanced cutaneous T cell lymphoma. Arch. Dermatol. 124:655-657; 1988.

6. Tyring, S., Guest, P., **Lee, P.**, Jaffe, K., Little, W. and Pritchett, R.: Epithelioid hemangioendothelioma of the skin and femur. J. Am. Acad. Dermatol. 20:362-366; 1989.

7. Tyring, S. and **Lee, P.**: Cutaneous vibrio infections. In: *Clinical Dermatology*. Eds: Demis, D., Bergdorf, W., Smith, E. and Thiers, B. Harper and Row, unit 16-53; 1989.

8. Tyring, S. and **Lee, P.**: Hemangiosarcoma and hemangioendotheliomas. In: *Clinical Dermatology*. Eds: Demis, D., Bergdorf, W., Smith, E. and Thiers, B. Harper and Row, unit 7-71, 1989.

9. Tyring, S., **Lee, P.**, Walsh, P., Garner, J. and Little, W.: Papular protothecosis of the chest: Immunologic evaluation and treatment with a combination of oral tetracycline and topical amphotericin B. Arch. Dermatol. 125:1249-1252; 1989.

10. Tyring, S. and **Lee, P.**: Protothecosis and Chlorellosis. In: *Clinical Dermatology*. Eds: Demis, D., Bergdorf, W., Raimer, S. and Thiers, B. J.B. Lippincott Company; Vol. 3, Section 17-30, pp.1-5, 1993.

11. Memar, O., **Lee, P.**, and Tyring, S.K.: Cutaneous manifestations of human immunodeficiency virus infection. J. Am. Podiatric Assoc. 85: 362-374; 1995.

12. Cirelli, R.A., **Lee, P.** and Tyring, S.K.: Therapy and prophylaxis of viral diseases with cutaneous manifestations. Canadian J. Dermatol. 7: 795-804; 1995.

13. Herne, K., Cirelli, R., **Lee, P.**, and Tyring, S.K.: Current experience with famciclovir for the treatment of herpesvirus infections. Today's Therapeutic Trends. 13: 29-37; 1995.

14. Herne, K., Cirelli, R., **Lee, P**. and Tyring, S.K.: Antiviral Therapy of Acute Herpes Zoster in Older Patients. Drugs and Aging. 8: 97-112; 1996.

15. Herne, K., Cirelli, R., **Lee, P**. and Tyring, S.K.: Current status of antiviral therapy. Current Opinion Dermatol., Third Edition. 3: 195-201; 1996.

16. Cirelli, R., Herne, K., McCrary, M., **Lee, P.** and Tyring, S.K.: Famciclovir: review of clinical efficacy and safety. Antiviral Res. 29:141-161; 1996.

17. Chopra, K., Glidden, A., **Lee, P**. and Tyring, S.K.: Second generation antiherpes drugs: valaciclovir and famciclovir. In: *Cutaneous Infection and Therapy*. Eds: Aly, R., Beutner, K. and Maibach, H. Marcel Dekker, Inc., Chapter 35, pp. 441-450, 1997.

18. Glidden, A., Chopra, K., **Lee, P.** and Tyring, S.K.: Interferons for treatment of genital warts. In: *Cutaneous Infection and Therapy*. Eds: Aly, R., Beutner, K. and Maibach, H. Marcel Dekker, Inc., Chapter 36, pp. 451-460, 1997.

19. Yan, J., Tyring, S.K., McCrary, M.M., **Lee, P.C.**, Haworth, S., Raymond, R., Olson, S.J., and Diasio, R.B.: The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. Clin. Pharmcol. Ther. 61:563-573, 1997.

20. Chopra, K.F., **Lee, P.C.** and Tyring, S.K.: Introduction to virus infections. In: *Clinical Dermatology*. Eds. Demis, D.J., Bergdorf, W., Smith, E.B., and Thiers, B.H. Harper and Row. Vol. 3, Section 14-0, pp. 1-16, 1997.

21. Chopra, K.F., **Lee, P.C.** and Tyring, S.K.: Herpes simplex. In: *Clinical Dermatology*. Eds. Demis, D.J., Bergdorf, W., Smith, E.B., and Thiers, B.M. Harper and Row. Vol. 3, Section 14-2, pp. 1-21, 1997.

22. Chopra, K.F., **Lee, P.C.** and Tyring S.K.: Kaposi's varicelliform eruption. In: *Clinical Dermatology*. Eds. Demis, D.J., Bergdorf, W., Smith, E.B. and Thiers, B.M. Harper and Row. Vol. 3, Section 14-3, pp. 1-7, 1997.

23. Vander Straten, M.R., **Lee, P. C.,** Weitzul, S., Cockerell, C.J., and Tyring, S.K.: Advances in the Treatment of Basal Cell Carcinoma: The Promise of Pharmacological Therapy Advances in Dermatology. Mosby, Inc., 16:299-319, 2000.

24. Severson, J., Evans, T., **Lee, P.**, Chan, T., Arany, I., and Tyring, S.K.: Human papillomavirus infections: epidemiology, pathogenesis, and therapy. J. Cut. Med. Surg. 5: 43-60; 2001.

25. Vander Straten, M.R., Carrasco, D.A., **Lee, P.C.,** and Tyring, S.K.: Reduction of Postherpetic Neuralgia in Herpes Zoster. J. Cutan. Med. Surg. (in press).

26. Vander Straten, M.R., **Lee, P.C.,** Cockrell, C., and Tyring, S.K.: Basal cell carcinoma – a review of current issues. Adv. Dermatol. (in press).

27. Vander Straten, M., Carrasco, D., **Lee, P.**, and Tyring, S.K.: A review of antiviral therapy for herpes labialis. Arch Dermatol (in press).

28. Brentjens, M.H., Sra, K.K, Haddad, V. Jr., **Lee, P.**, and Tyring, S.K.: Marine/freshwater dermatology. In: *Tropical Dermatology.* Eds: S.K. Tyring, O. Lupi and U.R. Hengge. Elsevier, London, pp. 455-468; 2006.

PRESENTATIONS

Presentations by research faculty, postdoctoral fellows, graduate and medical students working under the supervision of Dr. Tyring in the clinic and laboratory.

1. Carrasco, D., M. Vander Straten, T. Brown, **P. Lee,** and S.K. Tyring. Sexually transmitted diseases: diagnosis, treatment and prevention. 58th Annual Meeting, American Academy of Dermatology, San Francisco; March 10-15, 2000.

2. Vander Straten, M., D. Carrasco, **P. Lee,** and S.K. Tyring. Comparison of Valacyclovir and Famciclovir for treatment of acute herpes zoster. 58th Annual Meeting, American Academy of Dermatology, San Francisco; March 10-15, 2000.

3. Carrasco, D., M. Vander Straten, T. Brown, **P. Lee,** and S.K. Tyring. Sexually transmitted diseases: diagnosis, treatment and prevention. 58th Annual Meeting, American Academy of Dermatology, San Francisco; March 10-15, 2000.

4. Carrasco, D., M. Vander Straten, **P. Lee,** and S.K. Tyring. Sexually transmitted diseases in patients seropositive for HIV. 59th Annual Meeting, American Academy of Dermatology, Washington, D.C.; March 2-7, 2001.